公开(公告)号：US12128030B2

公开(公告)日：2024-10-29

申请号：US17271279

申请日：2019-08-27

申请人： HK INNO.N CORPORATION

发明人： Tae Keun Cho ,  Young Dae Cho ,  Eunji Kwon ,  Myung Jin Shin

IPC分类号： A61K31/4184 ,  A61K9/20 ,  A61K9/24 ,  A61K9/48 ,  A61K31/4365

CPC分类号： A61K31/4184 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/4866 ,  A61K31/4365

摘要： The present invention provides a pharmaceutical composition comprising clopidogrel or pharmaceutically acceptable salts thereof; and tegoprazan or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention has an advantage of maintaining a medicinal effect of clopidogrel while preventing or treating a side effect of clopidogrel, i.e., gastrointestinal disorders.

公开(公告)号：US20240307313A1

公开(公告)日：2024-09-19

申请号：US18609809

申请日：2024-03-19

申请人： Auspex Pharmaceuticals, Inc.

发明人： Parag Shah ,  Mayank Joshi ,  Soumen Pattanayek ,  Divyang Patel ,  Sandeep Pandita

IPC分类号： A61K9/24 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4745

CPC分类号： A61K9/209 ,  A61K9/0004 ,  A61K9/0053 ,  A61K9/2031 ,  A61K9/2077 ,  A61K31/4745

摘要： Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

公开(公告)号：US12064434B2

公开(公告)日：2024-08-20

申请号：US17805956

申请日：2022-06-08

申请人： Novartis AG

发明人： Rui Costa ,  Arnaud Grandeury ,  Bindhumadhavan Gururajan

IPC分类号： A61K31/519 ,  A61K9/20 ,  A61K9/28 ,  A61K31/496

CPC分类号： A61K31/519 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/284 ,  A61K31/496

摘要： The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an advanced moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

公开(公告)号：US20240238207A1

公开(公告)日：2024-07-18

申请号：US18416293

申请日：2024-01-18

申请人： Purdue Pharma L.P.

发明人： Haiyong Hugh Huang

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K9/24 ,  A61K9/28 ,  A61K31/485

CPC分类号： A61K9/2077 ,  A61K9/0053 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/28 ,  A61K31/485

摘要： In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

公开(公告)号：US20240197660A1

公开(公告)日：2024-06-20

申请号：US18550790

申请日：2022-03-31

申请人： B3AR THERAPEUTICS, INC.

发明人： Raymond E. STEVENS, Jr. ,  Dale BENNYHOFF

IPC分类号： A61K31/196 ,  A61K9/20 ,  A61K31/137 ,  A61K31/438

CPC分类号： A61K31/196 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/137 ,  A61K31/438

摘要： Disclosed herein are compositions and methods for treating overactive bladder. In some embodiments, the composition comprises an effective amount of micronized solabegron or a pharmaceutically acceptable salt or a derivative thereof. In some embodiments the micronized solabegron particles have a particle size of about 0.1 micron to 30 microns. In some embodiments, the administration of the pharmaceutical composition is twice daily.

公开(公告)号：US20240189234A1

公开(公告)日：2024-06-13

申请号：US18556513

申请日：2022-04-22

申请人： NACAMED AS

发明人： Werner FILTVEDT ,  Jo KLAVENESS ,  Hennie Marie JOHNSEN

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K9/50 ,  A61K31/155 ,  A61K31/165 ,  A61K31/343 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/436 ,  A61K31/522 ,  A61K31/573 ,  A61K31/635 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/00 ,  A61K38/13 ,  A61K47/61

CPC分类号： A61K9/1611 ,  A61K9/1694 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/5015 ,  A61K31/155 ,  A61K31/165 ,  A61K31/343 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/436 ,  A61K31/522 ,  A61K31/573 ,  A61K31/635 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/00 ,  A61K38/13 ,  A61K47/61

摘要： The invention provides a process for preparing silicon particles comprising at least one drug substance, wherein said process comprises the steps: a) preparing silicon particles via chemical vapor deposition (CVD): b) loading the silicon particles prepared in step a) with at least one drug substance.

公开(公告)号：US11992558B2

公开(公告)日：2024-05-28

申请号：US17261858

申请日：2019-07-21

申请人： Sushma Paul Berlia

发明人： Sushma Paul Berlia ,  Nishant Berlia ,  Anupama Diwan ,  Sunder Singh Bhandari

IPC分类号： A61K9/20 ,  A61J3/10 ,  A61K9/00 ,  A61K9/28 ,  A61K31/453

CPC分类号： A61K9/2077 ,  A61J3/10 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/2853 ,  A61K9/2893 ,  A61K31/453

摘要： The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free.

公开(公告)号：US20240156794A1

公开(公告)日：2024-05-16

申请号：US18412248

申请日：2024-01-12

申请人： Alkermes Pharma Ireland Limited

发明人： Sean Cunningham ,  Seamus Mulligan ,  Michael Myers

IPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/44 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/44 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

公开(公告)号：US11969426B2

公开(公告)日：2024-04-30

申请号：US17724045

申请日：2022-04-19

申请人： Genentech, Inc.

发明人： Reinhard Reents ,  Pirmin Hidber ,  Andre Hell ,  Peter Steidle ,  Martin Wunderlich ,  Marie Pepelnjak ,  Francis Gosselin ,  Edward Yost

IPC分类号： A61K31/517 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K31/517 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/28 ,  A61K9/284

摘要： The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.

公开(公告)号：US20240122857A1

公开(公告)日：2024-04-18

申请号：US17753657

申请日：2020-09-10

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Jing TAO ,  Anisha PATEL ,  Umesh KESTUR ,  Admassu ABEBE ,  Divyakant Shantilal DESAI

IPC分类号： A61K9/20 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K9/2077 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

摘要： The present application is directed to a pharmaceutical composition comprising (R)—N-(4-chlorophenyl)-2-((1S, 4S)-4-(6-fluoroquinolin-4-yl) cyclohexyl) propanamide methane sulfonic acid salt that is resistant to salt disproportionation: